Charmacy Pharmaceutical Co., Ltd. provided earnings guidance for the ended 31 December 2021. For the period, the group is expected to report a net profit attributable to the shareholders of the parent company of approximately RMB 21.00 million to RMB 25.00 million for the Year, representing a decrease of approximately 38% to 48% as compared with that of the year ended 31 December 2020.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.8 HKD | -35.77% | -34.13% | -32.10% |
21/05 | Charmacy Pharmaceutical to Pay Final Dividend | MT |
01/04 | Charmacy Pharmaceutical 2023 Profit Declines on Lower Asset Disposal Gains | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.10% | 190M | |
-38.05% | 14.21B | |
-29.16% | 11.58B | |
-27.59% | 6.51B | |
+13.06% | 6.32B | |
-8.13% | 6.15B | |
+71.17% | 4.98B | |
-6.68% | 3.97B | |
-12.41% | 3.43B | |
-9.81% | 2.96B |
- Stock Market
- Equities
- 2289 Stock
- News Charmacy Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Ended 31 December 2021